Zedoary turmeric oil (ZTO) is a volatile oil that is extracted from the dry rhizome of Curcuma zedoaria with a variety of biological activities, including antitumor activity. However, there is a lack of knowledge about the effect and mechanism of ZTO in human colon cancer cells. The aim of this study was to examine the potential efficacy of ZTO against human colon cancer cells (HCT116) and to uncover the molecular mechanisms of its anti-tumor effects. The anti-proliferative activity of ZTO was determined by the MTT assay, cell counts and colony formation assay. Senescent cells were detected using SA-β-Gal staining, while apoptosis and the CD44 + subpopulation were evaluated by flow cytometry. The expression levels of senescence-and apoptosis-related proteins were examined using western blotting. The results showed that treatment with ZTO significantly inhibited the growth of HCT116 cells and caused senescence and apoptosis in a dose-and time-dependent manner. Western blotting revealed that ZTO significantly increased the expression of senescence-and apoptosisrelated proteins p16, p21, and p53 and the phosphorylation of ERK. Moreover, ZTO treatment reduced the cancer stem-like CD44 positive cell population. These findings suggest that ZTO inhibits human colon cancer cells by inducing senescence and apoptosis.
Colon cancer is a common clinical malignant tumor of the digestive system and is one of the most common causes of cancer-related deaths worldwide, with over 1.4 million new cases each year [1] . In recent years, the colon cancer morbidity increased by nearly 5% every year, far exceeding the 2% international average standard. Colon cancer has obviously become one of the most dangerous killers and severely threatens the lives and health of many [2] . It is projected that from 2015 to 2030, the incidence of the disease in developing countries will increase by as much as 60%. Hence, the management of this cancer presents a great challenge [1b] .
Natural products play an important role in the discovery of novel lead compounds and new chemical entities, and much effort has been directed toward the search for compounds or herbs in natural products that kill tumors. Zedoary turmeric oil (ZTO), a volatile oil extracted from the dry rhizome of Curcuma zedoaria, shows a variety of pharmacological effects, including anti-tumor, antibacterial and anti-viral activities. The anti-tumor effect is the major pharmacological effect of ZTO [3] . In general, ZTO exerts its antitumor effect by inducing cell cycle arrest and apoptosis [4] . In the study, it showed strong inhibitory effects on HCT116 cells. Thus, we investigated the mechanism of its anti-tumor activities. We found that ZTO not only induced HCT116 cell apoptosis but also induced senescence, on which there is little information available in the literature. The results also revealed that the proteins ERK, p53, p21, and p16 participated in the senescence and apoptosis process induced by ZTO. In addition, the cell population that was positive for CD44, a cell surface marker of colon cancer stem cells [5] , decreased after ZTO treatment. Consequently, ZTO may be a promising chemotherapeutic agent against colon cancer.
The MTT assay and cell counts were used to evaluate the effect of ZTO on the proliferation and viability of the HCT116 cells. After treatment with the indicated concentrations of ZTO for 48 h, the cellular growth and viability of HCT116 exhibited strong inhibition by ZTO in a dose-dependent manner ( Figure 1A and B). The 50% inhibitory concentration (IC50) of ZTO on HCT116 cells was 101 μgꞏmL-1. Furthermore, HCT116 cells exposed to ZTO for 2 weeks were analyzed using a colony formation assay. The results showed that ZTO prevented the formation of colonies of HCT116 cells at the indicated concentrations ( Figure 1C and D) . Therefore, ZTO shows significant anti-proliferative effects on HCT116 cells.
To explore what mechanism is responsible for the anti-proliferative effect of ZTO, we used SA-β-Gal staining to test whether senescence was induced by ZTO. After cells were treated with ZTO, we used SA-β-Gal staining to observe the senescence-like phenotype. As shown in Figure 2 , many cells were positively stained upon ZTO exposure. Furthermore, ZTO induced senescence was dose (25, 50, and 100 μgꞏmL-1) and time (24, 48 and 72 h) dependent. This suggests that ZTO induces cellular senescence under these conditions. In addition to senescence, the Annexin V/PI double staining assay was used to test whether ZTO induced apoptosis. HCT116 cells were incubated with different concentrations (25, 50, and 100 μgꞏmL-1) of ZTO or with different times (24, 48 and 72 h). As shown in Figure 3 , the ZTO treatments resulted in a remarkable increase in the percentage of apoptotic cells. These data verify that ZTO induces apoptosis in HCT116 cells in a dose-and time-dependent manner. To understand the molecular mechanism of ZTO-induced senescence and apoptosis in HCT116 cells, we further investigated the possible molecular mechanisms involved. Senescence regulatory proteins were investigated to clarify the underlying mechanism, and significant increases in p16 and p21 protein expressions were found upon exposure to the agent. Furthermore, we explored the expression of p53, a well-known senescence-and apoptosis-related protein. The results of the western blotting showed that ZTO increased the p53 expression in a dose-dependent manner. In addition, we examined the phosphorylation of ERK, which is the upstream protein of p16, p21, and p53 and regulates cell proliferation, apoptosis and senescence. We found that ZTO also increased the phosphorylation of ERK in a dose-dependent manner (Figure 4) . Together, these findings indicate that the possible molecular mechanisms of ZTO-induced senescence and apoptosis involve the proteins ERK, p53, p21, and p16.
In addition to normal cancer cells, we also wanted to study whether ZTO could inhibit colon cancer stem cells. According to the literature, CD44 is a robust marker that is of functional importance for cancer initiation by colon cancer stem cells [5a] . As shown in Figure 5 , after treatment with 100 μgꞏmL-1 ZTO for 72 h, the CD44 + subpopulation decreased, whereas the CD44 -subpopulation increased. The data imply that the ZTO treatment reduced the cancer stem-like CD44 + cell population, which helped maintain the tumorigenic diversity in colon cancer [5c]. Traditional Chinese medicine has been widely used in cancer therapy [6] . For example, curcumin can inhibit human colorectal carcinoma (HCT-15) cells by inducing apoptosis [7] . ZTO, as a type of traditional Chinese medicine, has been widely used in anti-tumor research. The well-known mechanism of its anti-tumor effect was Zedoary turmeric oil induces senescence and apoptosis Natural Product Communications Vol. 13 (7) 2018 909 the induction of apoptosis. It was found that ZTO induces apoptosis in a variety of cancer cell lines, such as Lewis lung carcinoma cells [8] , gastric cancer cells [9] , and breast cancer cells [10] . In this study, we provide evidence to show that ZTO could induce HCT116 cell apoptosis with increased expression of p53, which is related to apoptosis, in a dose-and time-dependent manner. However, the percentage of apoptotic cells induced by ZTO was lower compared with gambogic acid [11] and quercetin [12] , but their tumor inhibition rates were similar. Thus, we assumed that there may be other mechanisms involved.
Cellular senescence is an irreversible cell cycle arrest. Senescent cells retain their metabolic activity but lose their proliferative capacity [13] . Senescence also presents in tumor cells [14] , and the induction of tumor cell senescence benefits tumor suppression [15] . Previous studies of cancer therapies showed that there are a variety of clinical anti-cancer drugs (such as doxorubicin and camptothecin) that could induce tumor cell senescence [16] . In this study, the cellular senescence of HCT116 cells induced by ZTO is demonstrated by an increased number of cells with positive SA-β-Gal staining, which is one of the most commonly used senescence markers [17a] . We found that the senescence caused by ZTO can be connected to the increase in p16 and p21 expression and the phosphorylation of ERK, which are associated with senescence [17] . Therefore, these findings suggest that ZTO inhibited human colon cancer cells not only by inducing apoptosis but also by inducing senescence. Although apoptosis induced by ZTO exists in many cancer cell lines, senescence has not been reported in other cancer cell lines. Hence, whether ZTO induces the senescence of other cancer cells should be further studied.
Collectively, our study suggests that ZTO inhibits tumors through a Cancer stem cells (CSCs) are shown to be responsible for the initiation and progression of tumors. Several key stem cell markers specified for colon cancer have been defined, such as CD44, CD133, CD24, ALDH1, and CD166 [18] , but which of these is best for identifying the tumor-initiating cells of human colon cancer remains controversial. In this study, CD44 was selected as a cell marker for colon cancer stem cells, and the CD44 + subpopulation decreased after ZTO treatment. However, it is unclear whether ZTO can inhibit colon cancer stem cells by inducing apoptosis in a similar manner as curcumin [19] or by other mechanisms. Therefore, the mechanism of ZTO suppressing colon cancer stem cells merits further investigation. Taken together, our results demonstrate that ZTO inhibits the growth and survival of human colon cancer HCT116 cells by inducing cellular senescence and apoptosis, providing evidence that ZTO may be a potential therapeutic tool to treat colon cancer.
Experimental
Reagents: ZTO was obtained from the Jiangsu Institute for Food and Drug Control (Nanjing, China). RPMI Medium 1640 was obtained from Gibco (Grand Island, NY, USA). Fetal bovine serum (FBS) was purchased from Cellmax (Nanjing, China). Penicillinstreptomycin mixed antibiotics was purchased from Beyotime (Nanjing, China). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-Htetrazolium bromide (MTT) was purchased from Biosharp (Nanjing, China). The SA-β-Gal staining assay kit was purchased from Beyotime (Nanjing, China). The annexin V-FITC/PI apoptosis detection kit was purchased from Vazyme Biotech CO., Ltd. (Nanjing, China). FITC anti-mouse CD44 antibody was from Biolegend (San Diego, CA). Primary antibodies against p16, p21, p53, ERK, p-ERK and β-actin as well as the peroxidase-conjugated goat anti-rabbit and goat anti-mouse secondary antibodies were purchased from SAB (Nanjing, China).
Cancer cell lines and culture: Human colon carcinoma cells (HCT116 cell lines) were obtained from the American Type Culture Collection (ATCC, USA). They were maintained in a monolayer culture in RPMI-1640 with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C with 5% CO 2 and 95% O 2 .
ZTO Treatment: ZTO (25, 50, and 100 μgꞏmL-1) was used for treatment in all assays. It was aliquoted into twenty EP tubes with 20 μL per tube, stored at 4°C, and diluted to the desired concentration with serum-free culture medium before each experiment.
MTT proliferation assay:
The cells were treated with the indicated concentrations of ZTO at 37°C for 48 h. Thereafter, MTT was added to reach a final concentration of 5 mgꞏmL-1 for 4 h. Then, the supernatant was removed, and the purple-colored formazan precipitate was dissolved in 150 µL DMSO and measured at 490 nm with a microplate reader (iMark, BIO-RAD).
Determination of viable cells:
The cells were seeded in a 12-well plate at 5×10 4 /mL for 24 h and then treated with the indicated concentrations of ZTO for 48 h. After incubation, the cells were digested with trypsin and resuspended with culture medium and then counted with count plates to determine the number of viable cells per milliliter.
Colony formation assay:
The cells treated with the indicated concentrations of ZTO were pipetted thoroughly to obtain a singlecell suspension in complete culture medium and were stored at room temperature until ready to use. To perform the colony formation assay, the culture medium containing cells was seeded into 6 cm diameter dishes (400 cells per dish), and the cells were incubated at 37°C in 5% CO 2 for 2 weeks. Thereafter, the colonies on the dish were fixed with 4% paraformaldehyde, stained with crystal violet and counted.
Senescence-associated β-galactosidase (SA-β-Gal) staining assay: To detect senescent cells, an SA-β-Gal staining assay kit was used according to the manufacturer's instructions. The cells in the 96-well plate were washed twice with PBS and incubated in 100 μL of fixing solution at room temperature for 15 min. After removing the fixing solution and washing the fixed cells three times with PBS, the cells were stained with 100 μL of freshly prepared cell staining working solution at 37°C without CO 2 overnight under protection from light. After staining, the cells were washed, and the senescent cells were identified as the blue-stained cells. At least 200 cells per field of vision were counted for each sample in three random fields to determine the percentage of SA-β-Gal positive cells.
Annexin V-FITC/PI double staining assay: HCT116 cells in different states were observed with an Annexin V-FITC/PI apoptosis detection kit by flow cytometry. The cells were treated with different concentrations of ZTO for different times. After incubation, the cells were collected, washed twice in cold PBS, and resuspended in 100 μL of binding buffer at 1×10 5 cells/mL. The samples were incubated with 5 μL of Annexin V-FITC and 5 μL of PI solution in the dark for 10 min at room temperature. Finally, all stained cells were analyzed on a flow cytometer (Calibur, BD Bioscience) and analyzed with FlowJo software (Tree Star).
Western blotting analysis:
Monolayer cultures of cell lines at 80%~90% confluence were lysed using 100 μL of cold RIPA buffer. For western blotting, the samples were loaded into 10% SDS-PAGE gels. After running gel electrophoresis, the gel was transferred to a polyvinylidene fluoride (PVDF) membrane for 2 h. The membrane was blocked for 2 h in 5% BSA (bovine serum 910 Natural Product Communications Vol. 13 (7) 2018 Su et al. albumin) and then washed five times with 1× TBST (tris-buffered saline containing 0.1% Tween 20) and incubated overnight with primary antibodies at 4°C followed by incubation with the corresponding HRP-conjugated secondary antibodies. Finally, the signal was visualized by Immobilon Western Chemiluminescent HRP Substrate.
Flow cytometry analysis for the CD44
+ subpopulation: HCT116 cells were treated with 100 μgꞏmL-1 ZTO for 72 h. After incubation, the cells were collected, washed twice in cold PBS, and resuspended in 100 μL of PBS at 1×10 6 cells/mL. The samples were incubated with 0.5 μL of FITC anti-mouse CD44 in the dark for 30 min at 4°C and then washed once with cold PBS, fixed with 4% paraformaldehyde for 30 min at 4°C, and then washed again with cold PBS. Finally, the samples were analyzed by flow cytometry and evaluated based on the percentage of cells in the R2 areas.
Statistical analysis:
All data represent at least three independent experiments. GraphPad Prism was used for statistical analysis, and the data were analyzed using Student's t test. Values were considered significantly different at P < 0.05.
